Demographic and disease characteristics, original randomisation groups, and treatment exposure in the lowest (MIN) and highest (MAX) quartiles of cumulative total dose of sc IFN β-1a (see also online supplementary tables S4 and S5 for characteristics at 24 and 48 months after randomisation)
| Cumulative dose of sc IFN β-1a (quartiles) | ||
|---|---|---|
| MIN (n=73) | MAX (n=72) | |
| Median (range) age,* years | 33.6 (20.4–50.3) | 36.6 (20.6–49.4) |
| Female, n (%) | 53 (72.6) | 46 (63.9) |
| White, n (%) | 72 (98.6) | 70 (97.2) |
| Median (range) time from MS onset,* years | 6.2 (1.0–24.2) | 5.2 (1.1–34.4) |
| Mean (SD) number of relapses in prior 2 years* | 3.1 (1.3) | 3.0 (1.0) |
| Mean (SD) EDSS score* | 2.5 (1.2) | 2.2 (1.0) |
| Original randomisation group, n (%) | ||
| IFN β-1a 44 µg | 14 (19.2) | 35 (48.6) |
| IFN β-1a 22 µg | 27 (37.0) | 14 (19.4) |
| Placebo | 32 (43.8) | 23 (31.9) |
| Mean (SD) time on sc IFN β-1a treatment,† years | 2.9 (1.9) | 14.7 (1.3) |
| Mean (SD) cumulative total dose of sc IFN β-1a,† mg | 12.3 (7.4) | 94.9 (10.4) |
| Use of other first-line DMDs,† n (%) | 38 (52.1) | 2 (2.8) |
*At baseline.
†At PRISMS-15.
DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; IFN, interferon; sc, subcutaneous.